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We evaluated the efﬁcacy and tolerability of Gosha-jinki-gan (GJG; 濟生腎氣丸 jì sheng shen qì wan) in
30 cases of nocturia (夜尿 ye niao) unresponsive to a1-blockers or antimuscarinic drugs. All patients
received GJG extract powder (2.5 g) three times a day for 12 weeks as an add-on therapy to a1-blockers
or antimuscarinic drugs. Subjective outcomes assessed by the International Prostate Symptom Score-
dquality of life, and the benign prostatic hyperplasia impact index and objective outcomes assessed by
urinary frequency and the urine production rate at night showed signiﬁcant improvement after treat-
ment. Moreover, other objective outcomes assessed by maximum ﬂow rates, postvoid residual, serum
human atrial natriuretic peptide levels, and urinary 8-hydroxy-20-deoxyguanosine levels did not change.
Adverse events were observed in 10% of cases; however, these events were mild. GJG appears to be a safe
and effective potential therapeutic alternative for patients with nocturia unresponsive to a1-blockers or
antimuscarinic drugs. Further clinical investigations are required to elucidate the precise pathophysio-
logic mechanisms of GJG in nocturia.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Bothersome nocturia (夜尿 ye niao) reduces quality of life (QOL)
and can lead to embarrassment, social anxiety, and poor self-
esteem.1 It is frequently associated with daytime drowsiness,
inability to concentrate, and decreased motivation to perform ac-
tivities.2 All these consequences are potential risks for depression.3
Nocturnal polyuria (NP) is an important cause of nocturia, and
about 70% of outpatients with nocturia have NP.4 Although the
detailed mechanism of NP has yet to be elucidated fully, low serum
arginineevasopressin levels during thenight andhigh serumhuman
atrial natriuretic peptide (hANP) levels can cause this condition.5
Although prebedtime vasopressin treatment is widely applied
to reduce nocturnal urine volume, adverse effects of hyponatremia
are not uncommon.6 Other options for NP are the application of
loop diuretics during the daytime and a Japanese traditionalDokkyo Medical University
ya, Saitama 343-8555, Japan.
for Food and Biomolecules,
molecules, National Taiwan Univeblended herbal medicine, Gosha-jinki-gan (GJG; 濟生腎氣丸 jì
sheng shen qì wan).7
GJG has been used widely and empirically in Japan to treat pa-
tients with lower urinary tract symptoms. Since this herbal drug
can be purchased over the counter, it is used as a traditional
medicine for nocturia. However, to the best of our knowledge, there
is little evidence on the efﬁcacy of this drug for nocturia treatment.8
In this study, we attempted to evaluate the efﬁcacy and safety of
GJG as an add-on therapy for elderly patients with nocturia resis-
tant to a1-blockers or antimuscarinic drugs. We evaluated patients
based on their International Prostate Symptom Score (IPSS), IPSS-
QOL, benign prostatic hyperplasia impact index (BII), uro-
ﬂowmetry results, frequencyevolume chart (FVC), serum hANP
levels, and urinary 8-hydroxy-20-deoxyguanosine (8-OHdG) levels.2. Materials and methods
2.1. Safety analysis
Prior to commencing the study, we obtained approval from the
Institutional Review Board. We obtained written informed consent
from all the participants after thoroughly explaining the efﬁcacy of
GJG and its possible adverse reactions such as hypersensitivity, liverrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline patient characteristics.
Age (y) 75.5 ± 5.1
Sex 24/6
Urinary frequency
24 h 12.1 ± 2.9
Nocturnal 4.4 ± 1.3
Urine volume
24 h (mL) 2088 ± 741
Nocturnal (mL) 951 ± 504
NPI 0.45 ± 0.14
HUS (min) 126 ± 58
24 h polyuria (>40 mL/kg) 5 (16.7%)
NP (NPI > 0.33) 25 (83.3%)
Decreased NBC 8 (26.7%)
NP þ decreased NBC 5 (16.7%)
HUS ¼ hours of undisturbed sleep; NBC ¼ nocturnal bladder capacity;
NP ¼ nocturnal polyuria; NPI ¼ nocturnal polyuria index.
Table 2
Effects of Gosha-jinki-gan on various voiding parameters.
Baseline After 12 wk p*
IPSS
Total 14.5 ± 6.2 10.4 ± 3.9 <0.001
Voiding symptoms 6.4 ± 4.6 4.3 ± 3.2 0.011
Storage symptoms 8.1 ± 2.9 6.1 ± 2.0 0.002
QOL 4.2 ± 1.2 3.3 ± 1.5 0.007
BII 6.3 ± 4.1 5.0 ± 3.4 0.024
UFM
Qmax (mL/s) 10.7 ± 10.0 10.3 ± 8.2 0.800
Voided volume (mL) 108 ± 73 113 ± 68 0.812
Residual volume (mL) 26 ± 26 24 ± 23 0.735
FVC
nocturia (夜尿 ye niao) 4.4 ± 1.3 3.5 ± 1.9 0.008
HUS (min) 126 ± 58 168 ± 88 0.058
NUV (mL) 951 ± 504 833 ± 496 0.087
NPI 0.45 ± 0.14 0.39 ± 0.16 0.009
hANP (pg/mL) 30.7 ± 22.3 30.9 ± 22.1 0.930
8-OHdG (ng/mLCRE) 16.9 ± 10.5 14.8 ± 6.5 0.221
BII ¼ benign prostatic hyperplasia impact index; FVC ¼ frequencyevolume
chart; hANP ¼ human atrial natriuretic peptide; HUS ¼ hours of undisturbed sleep;
IPSS ¼ International Prostate Symptom Score; NUV ¼ nocturnal urine volume;
NPI ¼ nocturnal polyuria index; QOL ¼ quality of life; UFM ¼ uroﬂowmetry;
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine.
Wilcoxon’s signed rank test.
* Two data samples are matched if they come from repeated observations of the
same subject. Using the Wilcoxon's signed rank test, we can decide whether the
corresponding data population distributions are identical without assuming them to
follow the normal distribution.
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tions. For monitoring side effects, levels of aspartate aminotrans-
ferase, alanine aminotransferase, serum creatinine, urea nitrogen,
uric acid, urinary blood, glucose, and ketone were investigated
prior to and after treatment.
2.2. Gosha-jinki-gan (GJG; 濟生腎氣丸 jì sheng shen qì wan)
GJG (TJ-107; Tsumura Co., Tokyo, Japan) is the extract product,
which included 4.5 g of the compound extracts of 10 herbal medi-
cines: RehmanniaeRadix (地黃dìhuang) (5g), AchyranthisRadix (牛
膝 niú xı) (3 g), Corni Fructus (山茱萸 shan zhu yú) (3 g), Dioscoreae
Rhizoma (山藥 shan yao) (3 g), Hoelen (Poria Cocos;茯苓 fú ling) (3
g), Plantaginis Semen (車前子 che qian zǐ) (3 g), Alismatis Rhizoma
(澤瀉 ze xie) (3 g), Moutan Cortex (牡丹皮 mǔ dan pí) (3 g), Cinna-
moni Cortex (桂皮 guì pí) (1 g), and heat-processed Processi Aconiti
Radix (附子 fù zǐ) (1 g). It is a standardized spray-driedwater extract,
which includes magnesium stearate, lactose, and fructose fatty acid
esters as diluents. The manufacturing process meets all re-
quirements of the Japanese and International GMP guidelines.
2.3. Eligibility and study design
Patients who consulted our hospital with lower urinary tract
symptoms between June 2013 and May 2014 were candidates for
enrollment. Inclusion criteria were as follows: (1) age  65 years;
(2)  2 voids per night despite treatment with a1-blockers or
antimuscarinic drugs for at least 4 weeks; (3) total IPSS  8; and
(4) IPSS-QOL  3. Patients with neurogenic bladder, urethral
stricture, and active urinary tract infection possibly affecting
voiding functions were excluded. All patients were administered
GJG 2.5 g preprandially for 12 weeks as an add-on therapy to a1-
blockers or antimuscarinic drugs. Prior to and after treatment, FVC
(3 consecutive days), IPSS, IPSS-QOL, BII, uroﬂowmetry, hANP, and
urinary 8-OHdG levels were examined. We then used the FVC data
to calculate the void frequency and voided volume over 24
continuous hours. The NP index was calculated by dividing
nocturnal urine volume by the total urine volume per day, and
hours of undisturbed sleep was deﬁned as the duration between
going to bed and the ﬁrst nocturnal void. The nocturnal bladder
capacity index was also calculated.9 Polyuria was deﬁned as pro-
ducing >40 mL/kg urine over a 24-hour period, and NP was
deﬁned as an NP index score of >0.33.10 As a marker of oxidative
stress, we evaluated urinary 8-OHdG levels using an ICR-001 de-
vice (Techno Medica, Yokohama, Japan) according to the manu-
facturer’s recommendations.
2.4. Statistical analysis
Data are reported as mean ± standard deviation and analyzed
using SPSS software, version 12.0 (IBM, Chicago, IL, USA). Wilcox-
on's signed rank test was used to evaluate the effect of treatment,
and p < 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of GJG
A total of 30 patients were included in this study. Table 1 shows
the baseline characteristics. The mean patient age ± standard de-
viation was 75.5 ± 5.1 years. Nocturnal frequency, urine volume,
and NP index were 4.4 ± 1.3 mL, 951 ± 504 mL and 0.45 ± 0.14 mL,
respectively. FVC scores revealed NP in 25 patients (83.3%),
decreased nocturnal bladder capacity in eight patients (26.7%), and
both NP and decreased nocturnal bladder capacity in ﬁve patients(16.7%). A summary of the effects of GJG on voiding functions is
listed in Table 2. Subjective outcomes assessed by total IPSS, IPSS-
QOL, and BII signiﬁcantly decreased after treatment. Both voiding
symptoms (intermittency, straining, weak stream, and incomplete
emptying) and storage symptoms (urgency, micturition frequency,
and nocturia (夜尿 ye niao)) improved after treatment (6.4 ± 4.4 vs.
4.3 ± 3.2, p ¼ 0.011 and 8.1 ± 2.9 vs. 6.1 ± 2.0, p ¼ 0.002, respec-
tively). Maximum ﬂow rates and voided volume from the baseline
did not change signiﬁcantly after treatmentdfrom 10.7 ± 10.0 to
10.3 ± 8.2, p ¼ 0.800, and from 108 ± 73 to 113 ± 68, p ¼ 0.812,
respectively. No signiﬁcant change in postvoid residual was
observed after treatment (26 ± 26 to 24 ± 23, p ¼ 0.735). Objective
outcomes, which included the number of nocturnal voids and the
urine production rate at night, were signiﬁcantly decreased, from
4.4 ± 1.3 to 3.5 ± 1.9, p ¼ 0.008 and from 0.45 ± 0.14 to 0.39 ± 0.16,
p ¼ 0.009, respectively. However, other objective parameters, such
as hours of undisturbed sleep, hANP, and urine 8-OHdG levels,
remained unchanged.
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Adverse reactions to the treatment were observed in three pa-
tients (10%). The symptoms were gastric discomfort in two patients
and nausea in one; all such cases were of mild severity (Grade 1)
and were followed up closely without therapy. No patients dis-
continued the treatment due to these adverse events.
4. Discussion
GJG, a pharmaceutical drug covered by National Health Insur-
ance, has been effective for patients with lumbago, edema of the
lower extremities, numbness, blurred vision, and lower urinary
tract symptoms. Traditionally, it was used as a medicine for kidney
function deﬁciency. Kidney keep one’s congenital energy, and, with
aging, this function is deteriorated. Therefore, it has been used
mainly for senile problems.
Studies have shown that either Hachimi-Jio-Gan (八味地黃丸 ba
wei dì huang wan) or GJG is effective for diabetic complications.
Yokozawa et al11e13 investigated that Hachimi-Jio-Gan had a pro-
tective effect against diabetic nephropathy in animal models. They
speculated that Hachimi-Jio-Gan promotes the formation of
advanced glycation end-product by Corni Fructus (山茱萸 shan zhu
yú) or suppression of oxidative stress.14 Moreover, GJG had shown
protective effects against diabetic complications in the animal
model or clinical setting.15e17 Watanabe et al16 showed that GJG
had some beneﬁcial effects on serum glucose and glycated hemo-
globin. Comparing the medications in two groups, they found that
the patients in the control group had more progressed medications
in 5 years (nonmedication to medication or medication to insulin).
Body mass index (BMI) was similar at the beginning of the study;
however, after 5 years, the GJG group retained their BMI and the
control group lost weight. These two facts support that serum
glucose was reduced in the GJG group, compared with the control
group. Because the difference in the blood serum glucose or gly-
cated hemoglobin was observed only in the late years, they
assumed that an improvement of insulin resistance might lead to a
decrease in the blood glucose level.18,19
The mechanism of GJG for nocturia (夜尿 ye niao) has long been
unclear. However, recent basic research is gradually clarifying the
mechanism of GJG for urinary frequency.20e24 Goto et al25 reported
that the effects of GJG on urinary frequency are associated with
inhibition of the micturition reﬂex and decline of bladder sensation
via the spinal kappa-opioid receptors. Among the ingredients of
GJG, Processi Aconiti Radix (附子 fù zǐ) from Aconitum carmichaelii
may be mainly responsible for the antinociceptive effect.24 In
addition, they hypothesized that other ingredients such as Planta-
ginis Semen (車前子 che qian zǐ) from Plantago asiatica (車前草 che
qian cǎo), Alismatis Rhizoma (澤瀉 ze xie) from Alisma orientale,
and Poria (茯苓 fú ling) from Poria cocos could be effective for
reducing urine production at night by regulating the distribution of
ﬂuid in the body.24 The FVC scores and hANP levels in this study
support this hypothesis.
Oxidative stress induces pathophysiological conditions in the
urinary bladder by damaging the urotheliumand sensitizing bladder
afferent signaling,26 and oxidative stress has been shown to induce
bladder hyperactivity by mediating capsaicin-sensitive C-ﬁbers.27
Therefore, eliminating oxidative stress might ameliorate such path-
ophysiological conditions and be a possible therapy for nocturia due
to lower urinary tract symptoms.28 As we did not evaluate the anti-
oxidative effects of GJG, further long-term studies are needed to
evaluate the effects of GJG as an antioxidative medicine.
The major limitations of this study are the small number of
patients, lack of a placebo-controlled group, and no urodynamic
data. In cases of lower urinary tract symptoms, which have a strongplacebo component, the possibility of a placebo effect might be
high. Therefore, it is difﬁcult to conclude that GJG is effective for
nocturia. To overcome these disadvantages, we need a large-scale
placebo-controlled prospective study.
5. Conclusion
GJG exerts an inhibitory effect on the micturition reﬂex, and is a
potentially safe and useful add-on treatment for patients with
nocturia (夜尿 ye niao) resistant to a1-blockers or antimuscarinic
drugs. However, further clinical investigations are required to
elucidate the precise mechanisms of GJG in nocturia
pathophysiology.
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